商品分类

浏览历史

B20564	黄芪甲苷
源叶	分析标准品,HPLC≥98%

英文名：
Astragaloside IV

别名：

CAS号：
84687-43-4

分子式：
C₄₁H₆₈O₁₄

分子量：
784.97

MDL：
MFCD16036240

核磁/质谱：

品牌	货号	产品规格	价格(RMB)	库存（上海）	北京	武汉	南京	计量单位	加入购物车...
源叶	B20564-20mg	分析标准品,HPLC≥98%	￥150.00元	>10	2	10	9	EA	加入购物车
源叶	B20564-100mg	分析标准品,HPLC≥98%	￥450.00元	>10	-	-	-	EA	加入购物车
源叶	B20564-2.5g	分析标准品,HPLC≥98%	￥4800.00元	>10	-	-	-	EA	加入购物车

大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》，到货后将短信提示。
提交

产品介绍

参考文献(103篇)

质检证书(COA)

摩尔浓度计算器

相关产品

介绍：
Astragaloside IV 是从黄芪中分离得到的一种皂苷，抑制ERK1/2和JNK激活，在乳腺癌细胞 MDA-MB-231 中，下调(MMP)-2和(MMP)-9的信号通路。

熔点： 295-296°C

沸点： 895.7 °C at 760 mmHg

比旋光度： +24.4°(c=0.23，甲醇)

外观：无色针晶

溶解性： DMSO : ≥ 100 mg/mL (127.39 mM)

储存条件： 2-8℃

注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

103. [3.8] Zicong Wu et al."Astragaloside IV Treats Parkinson’s Disease by Regulating the Proliferation and Differentiation of NSCs through the SHH–Nurr1 Pathway."Stem Cells International.2024 Sep;2024(1):2792909

102. [2.8] Zhu Yuanying et al."New insight into the molecular mechanism of TCM Bufei Huoxue formula for chronic obstructive pulmonary disease based on network pharmacology and experimental verification."JOURNAL OF PHARMACY AND PHARMACOLOGY.2024 Aug;:

101. [3.8] Li Wei et al."Quantitative comparison of bile acid glucuronides sub-metabolome between intrahepatic cholestasis and healthy pregnant women."ANALYTICAL AND BIOANALYTICAL CHEMISTRY.2024 Jul;:1-13

100. [5.6] Zuyu Lu et al."Physicochemical heterogeneity and mechanical separation of the phloem and xylem in Astragalus membranaceus."INDUSTRIAL CROPS AND PRODUCTS.2024 Dec;221:119182

99. [1.3] Hong-Ping Wang et al."Screening of potential α-glucosidase inhibitors from astragalus membranaceus by affinity ultrafiltration screening coupled with UPLC-ESI-Orbitrap-MS method."JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH.

98. [6] Jiaheng Shan et al."β-Cyclocitral from Lavandula angustifolia Mill. Exerts Anti-Aging Effects on Yeasts and Mammalian Cells via Telomere Protection, Antioxidative Stress, and Autophagy Activation."Antioxidants.2024 Jun;13(6):715

97. [6.7] Yinhuang Gao et al."Buqi Huoxue Tongnao prescription protects against chronic cerebral hypoperfusion via regulating PI3K/AKT and LXRα/CYP7A1 signaling pathways."PHYTOMEDICINE.2024 Sep;132:155844

96. [IF=10.2] Guo Hong et al."Homologous-magnetic dual-targeted metal-organic framework to improve the Anti-hepatocellular carcinoma efficacy of PD-1 inhibitor."JOURNAL OF NANOBIOTECHNOLOGY".2024 Dec;22(1):1-20

95. [IF=2.6] Fan Yang et al."Preliminary Exploration of Potential Active Ingredients and Molecular Mechanisms of Yanggan Yishui Granules for Treating Hypertensive Nephropathy Using UPLC-Q-TOF/MS Coupled with Network Pharmacology and Molecular Docking Strategy."Journal

94. [IF=5.5] Xiangyu Chen et al."Astragaloside IV combined with ligustrazine ameliorates abnormal mitochondrial dynamics via Drp1 SUMO/deSUMOylation in cerebral ischemia–reperfusion injury."CNS Neuroscience & Therapeutics".2024 Apr; 30(4): e14725

93. [IF=7.9] Yun Shan et al."The Role of Macrophage-Derived Exosomes in Reversing Peritoneal Fibrosis: Insights from Astragaloside IV."PHYTOMEDICINE".2024 Apr;:155683

92. [IF=10.8] Xiangtian Deng et al."Microenvironment-responsive smart hydrogels with antibacterial activity and immune regulation for accelerating chronic wound healing."JOURNAL OF CONTROLLED RELEASE".2024 Apr;368:518

91. [IF=5.4] Jialing Sun et al."Investigating the molecular mechanism of Qizhu anticancer prescription in inhibiting hepatocellular carcinoma based on high-resolution mass spectrometry and network pharmacology."JOURNAL OF ETHNOPHARMACOLOGY".2024 Feb;:117985

90. [IF=3.1] Yang Tao et al."Astragaloside IV modulates gut macrophages M1/M2 polarization by reshaping gut microbiota and SCFA in sepsis."SHOCK.2023 Nov;:10.1097/SHK.0000000000002262

89. [IF=5.2] Yang Ma et al."Astragaloside IV Attenuates Programmed Death-Ligand 1-Mediated Immunosuppression during Liver Cancer Development via the miR-135b-5p/CNDP1 Axis."Cancers.2023 Jan;15(20):5048

88. [IF=5.4] Keyan Jiao et al."Glycosides of Buyang Huanwu decoction inhibits inflammation associated with cerebral ischemia-reperfusion via the PINK1/Parkin mitophagy pathway."JOURNAL OF ETHNOPHARMACOLOGY.2024 Jan;:117766

87. [IF=5.4] Wenjuan Ma et al."Uncovering the key pharmacodynamic material basis and possible molecular mechanism of Xiaoke formulation improve insulin resistant through a comprehensive investigation."JOURNAL OF ETHNOPHARMACOLOGY.2024 Apr;323:117752

86. [IF=3.5] Yanyun Guan et al."Astragaloside IV inhibits epithelial-mesenchymal transition and pulmonary fibrosis via lncRNA-ATB/miR-200c/ZEB1 signaling pathway."GENE.2024 Mar;897:148040

85. [IF=17.1] Hong Guo et al."Magnetic Metal–Organic Framework-Based Nanoplatform with Platelet Membrane Coating as a Synergistic Programmed Cell Death Protein 1 Inhibitor against Hepatocellular Carcinoma."ACS Nano.2023;XXXX(XXX):XXX-XXX

84. [IF=3.1] Xi Jie et al."Astragaloside IV restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway."BMC Pulmonary Medicine.2023 Dec;23(1):1-12

83. [IF=3.1] Yuan Zhang et al."Isolating, Identifying, and Analyzing the Biological Characteristics of Pathogens Causing Postharvest Disease in Fresh Radix Astragali."Horticulturae.10.3390/horticulturae9091019

82. [IF=5.8] Xingru Peng et al."Novel mPEG-CS-modified flexible liposomes-reinforced thermosensitive sol-gel reversible hydrogels for ocular delivery of multiple drugs with enhanced synergism."COLLOIDS AND SURFACES B-BIOINTERFACES.10.1016/j.colsurfb.2023.113560

81. [IF=1.6] Lu Zhang et al."Astragaloside IV relieves IL-1β-induced human nucleus pulposus cells degeneration through modulating PI3K/Akt signaling pathway."MEDICINE.2023 Aug 18; 102(33): e34815

80. [IF=5.4] Huibo Dai et al."Network pharmacology, molecular docking and experimental verification of the mechanism of huangqi-jixuecao herb pair in treatment of peritoneal fibrosis."JOURNAL OF ETHNOPHARMACOLOGY.2023 Jul;:116874

79. [IF=3.1] Yanmin Wang et al."Study on the dynamic metabolic characteristic of main active ingredients in Danggui Buxue Decoction by liquid chromatography-tandem mass spectrometry based on in situ sequential metabolism strategy."JOURNAL OF SEPARATION SCIENCE.2023 Ju

78. [IF=4.6] Wei Li et al."Characterization of Metabolic Correlations of Ursodeoxycholic Acid with Other Bile Acid Species through In Vitro Sequential Metabolism and Isomer-Focused Identification."MOLECULES.2023 Jan;28(12):4801

77. [IF=5.195] Jiaxiong Yao et al."Systems pharmacology reveals the mechanism of Astragaloside IV in improving immune activity on cyclophosphamide-induced immunosuppressed mice."JOURNAL OF ETHNOPHARMACOLOGY.2023 Sep;313:116533

76. [6.656] Chuanjing Cheng et al."Astragaloside IV targets PRDX6, inhibits the activation of RAC subunit in NADPH oxidase 2 for oxidative damage."PHYTOMEDICINE.2023 Mar;:154795

75. [3.195] Yan, Fanchen et al."Glycoside combinations of Buyang Huanwu decoction ameliorate atherosclerosis via STAT3, HIF-1, and VEGF."NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY.2023 Jan;:1-17

74. [5.195] Zhen Xue et al."Untargeted metabolomics reveals the combination effects and mechanisms of Huangqi-fuzi herb-pair against doxorubicin-induced cardiotoxicity."JOURNAL OF ETHNOPHARMACOLOGY.2023 Apr;305:116109

73. [6.449] Yanmei Li et al."Regional variations and plant compartments shape the community structures of the endophytic microbiome and secondary metabolites of Astragalus mongholicus."INDUSTRIAL CROPS AND PRODUCTS.2023 Feb;192:116037

72. [IF=1.698] Jinyan Wu et al."Chemical Identification and Antioxidant Screening of Bufei Yishen Formula using an Offline DPPH Ultrahigh-Performance Liquid Chromatography Q-Extractive Orbitrap MS/MS."International Journal of Analytical Chemistry.2022 Oct 15;2022:142380

71. [IF=5.168] Pan Wang et al."Discovery and characterization of novel ATP citrate lyase inhibitors from natural products by a luminescence-based assay."CHEMICO-BIOLOGICAL INTERACTIONS.2022 Nov;367:110199

70. [IF=3.887] Xiang-Lin KONG et al."Effect of astragaloside IV and salvianolic acid B on antioxidant stress and vascular endothelial protection in the treatment of atherosclerosis based on metabonomics."Chinese Journal of Natural Medicines.2022 Aug;20:601

69. [IF=6.656] Xinying Fu et al."Glycosides from Buyang Huanwu Decoction inhibit atherosclerotic inflammation via JAK/STAT signaling pathway."PHYTOMEDICINE.2022 Oct;105:154385

68. [IF=4.769] Xinyi Chai et al."Screening of immune cell activators from Astragali Radix using a comprehensive two-dimensional NK-92MI cell membrane chromatography/C18 column/time-of-flight mass spectrometry system."Journal of Pharmaceutical Analysis. 2022 May;:

67. [IF=4.451] Liang Wang et al."Astragaloside IV protects diabetic cardiomyopathy against inflammation and apoptosis via regulating TLR4/MyD88/NF-κB signaling pathway."J Funct Foods. 2022 Jan;88:104905

66. [IF=3.168] Yuqiong Lin et al."Astragaloside IV Ameliorates Streptozotocin Induced Pancreatic β-Cell Apoptosis and Dysfunction Through SIRT1/P53 and Akt/GSK3β/Nrf2 Signaling Pathways."Diabet Metab Synd Ob. 2022 Jan;15:131-140

65. [IF=4.432] Hua Tian et al."Astragaloside IV protects against C/EBP homologous protein-mediated apoptosis in oxidized low-density lipoprotein-treated macrophages by promoting autophagy."Eur J Pharmacol. 2022 Mar;:174912

64. [IF=1.662] Hui Shi et al."Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway."J Food Biochem. 2021 Jul;45(7):e13757

63. [IF=3] Qu Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950

62. [IF=3.098] Haifeng Jin et al."Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling."Int J Mol Med. 2021 Feb;47(2):595-606

61. [IF=3.434] Du Xiaoxun et al."Tanshinone IIA and Astragaloside IV Inhibit miR-223/JAK2/STAT1 Signalling Pathway to Alleviate Lipopolysaccharide-Induced Damage in Nucleus Pulposus Cells."Dis Markers. 2021;2021:6554480

60. [IF=3.69] Jingyi Hu et al."Qingchang Huashi Formula attenuates DSS-induced colitis in mice by restoring gut microbiota-metabolism homeostasis and goblet cell function."J Ethnopharmacol. 2021 Feb;266:113394

59. [IF=3.69] Xiaoping Wang et al."Baoyuan decoction ameliorates apoptosis via AT1-CARP signaling pathway in H9C2 cells and heart failure post-acute myocardial infarction rats."J Ethnopharmacol. 2020 Apr;252:112536

58. [IF=3.7] Jing-Jing Yang et al."Astragaloside IV enhances GATA-4 mediated myocardial protection effect in hypoxia/reoxygenation injured H9c2 cells."Nutr Metab Cardiovas. 2020 May;30:829

57. [IF=3.882] Kunpeng Yin et al."Lanthanide Metal–Organic Framework-Based Fluorescent Sensor Arrays to Discriminate and Quantify Ingredients of Natural Medicine."Langmuir. 2021;37(17):5321–5328

56. [IF=3.935] Yu-li Jiang et al."HPLC fingerprinting-based multivariate analysis of chemical components in Tetrastigma Hemsleyanum Diels et Gilg: Correlation to their antioxidant and neuraminidase inhibition activities."J Pharmaceut Biomed. 2021 Oct;205:114314

55. [IF=4.225] Zhang Wei et al."Five Active Components Compatibility of Astragali Radix and Angelicae Sinensis Radix Protect Hematopoietic Function Against Cyclophosphamide-Induced Injury in Mice and t-BHP–Induced Injury in HSCs."Front Pharmacol. 2019 Aug;0:936

54. [IF=4.36] Pin Gong et al."Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway."J Ethnopharmacol. 2021 Dec;281:114558

53. [IF=6.081] Tongji Liu et al."Improvement Effect of Lotus Leaf Flavonoids on Carbon Tetrachloride-Induced Liver Injury in Mice."Biomedicines. 2020 Feb;8(2):41

52. [IF=1.146] Han Gao et al."Proliferation and committed differentiation into dopamine neurons of neural stem cells induced by the active ingredients of radix astragali."Neuroreport. 2018 May 2; 29(7): 577–582

51. [IF=3.098] Xiao Chen et al."Astragaloside IV ameliorates high glucose‑induced renal tubular epithelial‑mesenchymal transition by blocking mTORC1/p70S6K signaling in HK‑2 cells."Int J Mol Med. 2019 Feb;43(2):709-716

50. [IF=4.213] Qiangyuan Fan et al."Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: Preparation by supercritical fluid technology and evaluation in vitro and in vivo."Int J Pharmaceut. 2018 Dec;552:360

49. [IF=4.354] Ting Liu et al."Synthetic Access Toward Cycloastragenol Glycosides."J Org Chem. 2017;82(8):4170–4178

48. [IF=4.759] Yuping Zhang et al."On-line surface plasmon resonance-high performance liquid chromatography–tandem mass spectrometry for analysis of human serum albumin binders from Radix Astragali."J Chromatogr A. 2013 Jun;1293:92

47. [IF=7.514] Yuping Zhang et al."Integration of magnetic solid phase fishing and off-line two-dimensional high-performance liquid chromatography–diode array detector–mass spectrometry for screening and identification of human serum albumin binders from Radix Astragali

46. Yang, Jing-Jing, et al. "Astragaloside IV enhances GATA-4 mediated myocardial protection effect in hypoxia/reoxygenation injured H9c2 cells." Nutrition, Metabolism and Cardiovascular Diseases 30.5 (2020): 829-842.https://doi.org/10.1016/j.numecd.2020.01.00

45. Fan, Qiangyuan, et al. "Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: preparation by supercritical fluid technology and evaluation in vitro and in vivo." International journal of pharmaceutics 552.1-2 (201

44. Ting Liu, Jin-Xi Liao, Yang Hu, Yuan-Hong Tu, and Jian-Song Sun The Journal of Organic Chemistry 2017 82 (8), 4170-4178 DOI: 10.1021/acs.joc.7b00080

43. Liu, Tongji, et al. "Improvement effect of lotus leaf flavonoids on carbon tetrachloride-induced liver injury in mice." Biomedicines 8.2 (2020): 41.https://doi.org/10.3390/biomedicines8020041

42. Wang, Xiaoping, et al. "Baoyuan decoction ameliorates apoptosis via AT1-CARP signaling pathway in H9C2 cells and heart failure post-acute myocardial infarction rats." Journal of ethnopharmacology 252 (2020): 112536.https://doi.org/10.1016/j.jep.2019.112536

41. 范小龙,陈冉,吴婉琴,刘国姣,黄坤,江丰.液相色谱串联质谱法测定食品中淫羊藿苷等20种功能成分[J].食品与机械,2021,37(01):86-93+98.

40. 田文仓. 不同生长年限及采收期子洲黄芪鉴别特征及其质量、产量差异分析[D].北京中医药大学,2020.

39. 徐芳芳,张秀莉,侯滔,曲腊腊,王纪霞,刘艳芳,梁鑫淼.天然产物中FFA1受体新激动剂的发现与研究[J].上海中医药大学学报,2021,35(01):12-19. [4]宫梦琪,孙倩,李振.天麻中天麻素提取工艺优化及抑制α-葡萄糖苷酶活性研究[J].中国果菜,2020,40(09):14-17+23.

38. 彭胜男,陶琰心,洪婷,杨海燕,黄青.黄芪甲苷通过mTORC1通路调控IgA肾病大鼠脾淋巴细胞分化[J].中国免疫学杂志,2021,37(04):421-425.

37. 张悦,于学炜,于宏川,仲伟一,杨阳.黄芪甲苷调节miR-21基因抑制肾癌细胞增殖和诱导细胞凋亡的机制探讨[J].现代肿瘤医学,2020,28(18):3145-3150.

36. 曾广伟,安慧仙,方东,高钊,贾建军,朱舜明.黄芪甲苷抑制缺血再灌注诱导的大鼠心肌细胞凋亡[J].现代生物医学进展,2020,20(24):4612-4617.

35. 彭胜男,陶琰心,洪婷,杨海燕,黄青.黄芪甲苷通过mTORC1通路调控IgA肾病大鼠脾淋巴细胞分化[J].中国免疫学杂志,2021,37(04):421-425.

34. 冯美杰,李蕾,王颖航,徐兢鸿,潘志.黄芪甲苷对人类风湿关节炎成纤维样滑膜细胞增殖及白细胞介素6分泌的影响[J].中国中医基础医学杂志,2020,26(10):1484-1487.

33. 程欢,米雅慧,刘明平,于洋,黎同明.黄芪多糖、黄芪甲苷对大黄酸肠吸收的影响[J].中药新药与临床药理,2021,32(02):240-244.

32. 姚萱航,刘翠晶,常晶茹,张雪薇,刘霞.2种类型膜荚黄芪主要药效成分含量及关键酶基因表达量差异研究[J].中草药,2021,52(07):2072-2081.

31. 冯紫薇. 子洲黄芪饮片质量等级标准研究[D].北京中医药大学,2020.

30. 赵宏月,张东伟,庞琳琳,张欢,于睿.黄芪甲苷及人参皂苷Rg1对高脂大鼠心肌缺血再灌注损伤后心肌细胞凋亡的影响[J].辽宁中医杂志,2021,48(02):188-191.

29. 孙乐,吴鹏,王春艳,张学兰,金玉翠,刘海滨.黄芪饮片炮制工艺优选[J].时珍国医国药,2020,31(07):1616-1619.

28. 张素清,陈冰,陈思邈,董静怡,陈伟燕,张宇燕.R语言与正交试验分析处理优化黄芪中黄芪甲苷提取工艺的比较[J].中国中医急症,2020,29(08):1420-1423.

27. 支旭然刘洪涛吴茵等. UPLC-MS/MS法同时测定肾康注射液中7个有效成分[J]. 药物分析杂志 2017 037(001):37-42.

26. 燕玉奎, 郭玫, 邵晶,等. 红芪及其不同提取部位中主要活性成分的含量测定[J]. 中兽医医药杂志, 2020, v.39;No.220(01):22-25.

25. 张婕,梁程程,杨爱仲,齐聪.增免抑瘤方及有效组分对卵巢癌干细胞裸鼠移植瘤Notch/Jagged1信号通路的影响[J].中国实验方剂学杂志,2020,26(15):46-53.

24. 邹龙, 李欢欢, 刘辉,等. 补阳还五汤总苷胶囊的制备工艺优选. 中国实验方剂学杂志.

23. 邹龙刘辉李仲秋等. HPLC测定补阳还五汤总苷中黄芪甲苷和芍药苷的含量[J]. 湖南中医药大学学报 2012 32(005):39-42.

22. 李富欣, 于蓓蓓, 刘瑾,等. 茯黄颗粒的质量标准研究[J]. 西部中医药, 2019, 032(002):P.44-48.

21. 何昊许畅王兴中苏力张家旭. 四种不同方法提取黄芪中黄芪甲苷的对比研究[J]. 化工科技(3期):25-28.

20. 韦赫, 程林, 吴培,等. 黄芪皂苷生物合成对短期水分变化的响应[J]. 中国中药杂志, 2019, 44(03):39-45.

19. 李杨, 郭超, 张小平,等. 黄芪皂苷-氢氧化铝佐剂复合物对bFGF肿瘤疫苗抗乳腺癌活性的影响[J]. 河西学院学报, 2018, 34(05):32-37.

18. 成鹏,白银亮,胡彩莉,连佛彦,周海宇.黄芪甲苷通过调控FoxO3a/Wnt2/β-catenin通路抑制去卵巢大鼠骨质疏松的作用[J].中国实验方剂学杂志,2018,24(15):161-166.

17. 张悦,于学炜,于宏川,仲伟一,杨阳.黄芪甲苷调节miR-21基因抑制肾癌细胞增殖和诱导细胞凋亡的机制探讨[J].现代肿瘤医学,2020,28(18):3145-3150.

16. 张怡, 靳晓飞, 周晓红,等. 黄芪甲苷调控自噬抑制缺氧缺糖/复氧复糖HT22细胞凋亡[J]. 中国药理学通报, 2019, 035(004):519-524.

15. 俞曼殊, 史俊, 赵君谊,等. 黄芪甲苷调控Akt信号通路阻抑人腹膜间皮细胞间充质转化的实验研究[J]. 南京中医药大学学报, 2019, 35(01):53-57.

14. 刘晨旭,张玫,杨洋,魏鹏翔,魏群利.黄芪甲苷对高糖诱导下大鼠肾小球系膜细胞TGF-β1/Smad信号通路的影响[J].徐州医科大学学报,2019,39(09):641-643.

13. 贾力维, 沃晓嫚, 王谦博,等. 黄芪甲苷对非小细胞肺癌A549细胞增殖及凋亡相关蛋白表达的影响[J]. 黑龙江大学自然科学学报, 2019, 036(001):84-89.

12. 熊莉,吕梦娟,窦德宇,马玉红.黄芪甲苷对血管紧张素Ⅱ诱导肾小球系膜细胞增殖及炎症因子表达的影响[J].中国应用生理学杂志,2018,34(05):414-417+421.

11. 赵彩萍,刘翠玲,梁爽,李欣蓉,柳雪蕾,朱美玲.黄芪甲苷对脂多糖诱导人胃黏膜上皮细胞GES-1的抗炎作用及机制研究[J].中药新药与临床药理,2020,31(08):918-923.

10. 张吉, 臧东钰. 黄芪甲苷对急性肺损伤大鼠内质网应激介导影响[J]. 中国民族民间医药, 2014, 000(015):19-20.

9. 武建毅, 沈清, 金赟洁,等. 黄芪甲苷对BALB/C小鼠肝癌H22腹水瘤抑制作用及机制[J]. 中国药物警戒, 2016, 13(003):138-142.

8. 朱易平, 李茹柳, 时玉霞,等. 黄芪总皂苷对IEC-6细胞增殖及相关蛋白表达的影响[J]. 中药新药与临床药理, 2019, 30(01):60-65.

7. 倪琳, 魏学冰, 陈德道,等. 黄芪乌梅降糖颗粒的制备工艺与质量分析[J]. 海峡药学, 2020, v.32;No.240(01):10-15.

6. 李玉美, 陈新梅, 徐溢明,等. 纳秒脉冲电场灭菌对舒心糖浆质量影响的初步研究[J]. 化工时刊, 2015(04):31-32+52.

5. 孟琦, 宝丽, 张烨,等. 基于肠道菌群调节的小檗碱和黄芪甲苷联用降糖机制研究[J]. 食品与药品, 2020(3):169-175.

4. 孙铭忆, 李冰韶, 王永洁,等. 基于模糊层次分析法优选复方黄芪水浸膏提取工艺路线[J]. 中草药, 2018.

3. 陈开, 周静, 李敏,等. 基于大孔树脂的黄芪中黄芪甲苷提取液纯化工艺研究[J]. 中国中医急症, 2017, 26(011):1881-1883.

2. 袁一凡陈晓月刘保霞刘笑李瑞宏祁金龙贾庆忠.UPLC-MS/MS法同时测定康艾注射液中11种成分[J].中草药 2017 48(13):2660-2665.

1. 张素清陈冰陈思邈等. R语言与正交试验分析处理优化黄芪中黄芪甲苷提取工艺的比较[J]. 中国中医急症 2020(8).